九洲药业：控股子公司获得枸橼酸西地那非口崩片药品注册证书

Core Viewpoint - The company, Jiuzhou Pharmaceutical, announced that its subsidiary, Zhejiang Jiuzhou Biopharmaceutical Co., Ltd., has received the drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration of China [1] Group 1: Company Developments - The drug is an iterative formulation of Sildenafil developed by Pfizer, which was approved for import in China in 2019 [1] - Jiuzhou Pharmaceutical has invested approximately 13.52 million RMB in the research and development of Sildenafil Citrate Orally Disintegrating Tablets [1] - The acquisition of the drug registration certificate enhances the company's product pipeline and market competitiveness, although it is not expected to have a significant impact on the company's performance in the short term [1] Group 2: Market Context - The total sales revenue (end-user price) of Sildenafil Citrate tablets in the domestic medical and retail market reached 5.217 billion RMB in 2023 [1] - Major competitors in the market that have also received the drug registration certificate include Sichuan Kelun Pharmaceutical Co., Ltd. and Guangdong Tianenkang Pharmaceutical Co., Ltd. [1]